Azacosterol: Diaza derivative of cholesterol which acts as a hypocholesteremic agent by blocking delta-24-reductase, which causes the accumulation of desmosterol.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Acidobacteria: A physiologically diverse phylum of acidophilic, gram-negative bacteria found in a wide variety of habitats, but particularly abundant in soils and sediments.Immunoglobulin Light Chains: Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.MicroRNAs: Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing.Creatine Kinase: A transferase that catalyzes formation of PHOSPHOCREATINE from ATP + CREATINE. The reaction stores ATP energy as phosphocreatine. Three cytoplasmic ISOENZYMES have been identified in human tissues: the MM type from SKELETAL MUSCLE, the MB type from myocardial tissue and the BB type from nervous tissue as well as a mitochondrial isoenzyme. Macro-creatine kinase refers to creatine kinase complexed with other serum proteins.Creatine Kinase, MM Form: An isoenzyme of creatine kinase found in the MUSCLE.
Alteration of cholesterol biosynthetic pathways in the skin of mice administered polycyclic aromatic hydrocarbons. (1/4)When polycyclic aromatic hydrocarbons were applied solely or together with a tumor promoter (12-O-tetradecanoylphorbol-13-acetate) to the skin of mice, a marked decrease in the level of lathosterol was observed, reflecting a significant change in the metabolism of sterols. Yet the total amount of cholesterol was not changed. When diazacholesterol (a metabolic inhibitor) was administered to mice, both desmosterol and 5 alpha-cholesta-7,24-dien-3 beta-ol accumulated in the skin, whereas the level of lathosterol decreased. These results seem to suggest that a significant portion of lathosterol is formed via 5 alpha-cholesta-7,24-dien-3 beta-ol in addition to the pathway through methostenol. When polycyclic aromatic hydrocarbon was applied to the skin of the mouse treated with diazacholesterol, a significant increase of desmosterol and a marked drop of the level of 5 alpha-cholesta-7,24-dien-3 beta-ol were observed. These results strongly suggest that polycyclic aromatic hydrocarbons perturb the metabolism of sterol in the skin of mice while keeping the total amount of cholesterol unchanged. A similar metabolism also seems to be operating in tumor tissue itself. (+info)
Metabolic interconversion of free sterols and steryl esters in Saccharomyces cerevisiae. (2/4)The interconversion of free and esterified sterols was followed radioisotopically with [U-14C]acetate and [methyl-14C]methionine. In pulse-chase experiments, radioactivity first appeared mainly in unesterified sterols in exponential-phase cells. Within one generation time, the label equilibrated between the free and esterified sterol pools and subsequently accumulated in steryl esters in stationary-phase cells. When the sterol pools were prelabeled by growing cells aerobically to the stationary phase and the cells were diluted into unlabeled medium, the prelabeled steryl esters returned to the free sterol form under several conditions. (i) During aerobic growth, the prelabeled sterols decreased from 80% to 45% esters in the early exponential phase and then returned to 80% esters as the culture reached the stationary phase. (ii) Under anaerobic conditions, the percentage of prelabeled steryl esters declined continuously. When growth stopped, only 15% of the sterols remained esterified. (iii) In the presence of an inhibitor of sterol biosynthesis, which causes accumulation of a precursor to ergosterol, prelabeled sterols decreased to 40% steryl esters while the precursor was found preferentially in the esterified form. These results indicate that the bulk of the free sterol and steryl ester pools are freely interconvertible, with the steryl esters serving as a supply of free sterols. Furthermore, there is an active cellular control over what types of sterol are found in the free and esterified sterol pools. (+info)
Effects of steroid blockers on LH-induced ovulation in the domestic fowl, Gallus domesticus. (3/4)The spontaneous ovulation of hens was suppressed by daily injection of PMSG. The LH injected to overcome the block was accompanied by one of 4 compounds known to inhibit steroidogenesis at different sites in the biosynthetic pathway. A dose of 300 mg aminoglutethimide phosphate, which inhibits the conversion of cholesterol to 20 alpha-hydroxycholesterol, blocked the LH-induced ovulation and prevented the normal rise in plasma progesterone. Metyrapone, an inhibitor of 11 beta-hydroxylase, and SC 12937 and AY 9944, inhibitors of cholesterol synthesis, did not prevent ovulation or the progesterone rise induced by exogenous LH. Administration of progesterone overcame the inhibitory effect of aminoglutethimide, and it is suggested that progesterone is involved in the ovulatory process of the fowl. (+info)
Effect of a chemical carcinogen and phorbol esters on sterol metabolism of mouse skin. (4/4)The effect of 20-methylcholanthrene and phorbol esters on sterol metabolism of mouse skin was studied. When 4 beta-phorbol esters were administered to mice that were previously painted once with 20-methylcholanthrene, a depression of some sterols in skin occurred, of which that of lathosterol was most marked. This effect was not observed when the order of application was reversed. Using a metabolic inhibitor, diazacholesterol, it was shown that sterols which reduce in mouse skin by administration of carcinogen and promoters were similar to those which reduce by administration of carcinogen only and are the members of one of the two cholesterol-biosynthetic pathways, i.e., a pathway which proceeds through intermediates with a saturated side chain. The intensity of the lathosterol-depressing effect of phorbol esters depends on the order of application of 20-methylcholanthrene and promoters, the amount of promoters, molecular species of alcoholic moiety of esters, and configuration at C-4 of phorbol moiety. Of the phorbol esters tested, 4 beta-phorbol-12-myristate-13-acetate revealed the highest activity, which was followed by 4 beta-phorbol-12,13-didecanoate, 4 beta-phorbol-12,13-dibutyrate, 4 beta-phorbol-12,13-dibenzoate, 4 beta-phorbol-12,13-diacetate, 4 alpha-phorbol-12,13-didecanoate, and 4 alpha-phorbol. 4 alpha-Phorbol was practically inactive. When beta-naphthoflavone was substituted for 20-methylcholanthrene, little effect was observed except in TPA, which revealed a rather marked lathosterol-depressing activity. Phorbol esters themselves did show some activity of lathosterol depression without prior application of 20-methylcholanthrene, but the effects were much weaker. When anthralin was applied to mouse skin after the painting of 20-methylcholanthrene, a low but definite lathosterol-depressing effect was observed. (+info)
... (INN), or azacosterol hydrochloride (USAN) (brand name Ornitrol), also known as 20,25-diazacholesterol, is a ... Azacosterol acts as an inhibitor of 24-dehydrocholesterol reductase (24-DHCR), preventing the formation of cholesterol from ...
The developers of triparanol jokingly referred to it as a "non-estrogenic estrogen". Azacosterol Desmosterolosis X-linked ...
Unlike late-stage cholesterol biosynthesis inhibitors like triparanol and azacosterol, no accumulation of sterols has been ...
24-Dehydrocholesterol reductase (24-DHCR) inhibitors such as azacosterol and triparanol inhibit the production of cholesterol ...
List of MeSH codes (D10)
... azacosterol MeSH D10.570.938.208.160 --- cholestanol MeSH D10.570.938.208.222 --- cholesterol, dietary MeSH D10.570.938.208.250 ...
List of drugs: As-Az
... azacosterol (INN) Azactam azacyclonol (INN) azaftozine (INN) Azahexal (Hexal Australia) [Au], also known as azathioprine. ...
List of MeSH codes (D04)
... azacosterol MeSH D04.808.247.808.197.135 --- cholestanol MeSH D04.808.247.808.197.200 --- cholesterol esters MeSH D04.808. ... azacosterol MeSH D04.808.247.222.284.200 --- cholesterol esters MeSH D04.808.247.222.284.478 --- hydroxycholesterols MeSH ...
During his 2 decades as a clinical and basic research scientist at the National Heart Institute, Don Fredrickson was part of a remarkable team that helped transform our understanding of the pathophysiology of cardiovascular disease. The work of this team was instrumental in creating the field of lipidology and establishing the foundation for present-day approaches to the management of lipid disorders. Don also trained a generation of international basic and clinical research scientists, fostering their careers in immeasurable ways. These investigators are now among the worlds preeminent lipidologists.. After his early work on sterol metabolism, Don studied the structure and metabolism of the plasma lipoproteins, their role in fat transport, and the genetic factors that regulate their metabolism and concentration in the blood (personal communication, NIH, July 23, 2002). He participated in research on apolipoproteins A, B, and C, including the separation of apolipoproteins A and C into their ...
Thank you for your interest in spreading the word about Biochemical Journal.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Easy to read patient leaflet for Deep Sea Nasal Spray. Includes indications, proper use, special instructions, precautions, and possible side effects.
Azacosterol - Wikipedia
Azacosterol (INN), or azacosterol hydrochloride (USAN) (brand name Ornitrol), also known as 20,25-diazacholesterol, is a ... Azacosterol acts as an inhibitor of 24-dehydrocholesterol reductase (24-DHCR), preventing the formation of cholesterol from ...https://en.wikipedia.org/wiki/Azacosterol
Category:Sterols - Wikimedia Commons
Azacosterol molecule ball.png 2,023 × 1,000; 448 KB. *. Azacosterol molecule skeletal.png 2,366 × 1,000; 239 KB. ...https://commons.wikimedia.org/wiki/Category:Sterols
Triparanol - Wikipedia
The developers of triparanol jokingly referred to it as a "non-estrogenic estrogen". Azacosterol Desmosterolosis X-linked ...https://en.wikipedia.org/wiki/Triparanol
ȭ?? ????? , ??ȭ????ǰ , ȭ?? , ȭ???? Ʈ ?????????? Ʈ, ȭ?????? ü, ȭ???? ?? ????? , ??ȭ?? ??? , ȭ????ǰ ???, CAS No.,...
Azacosterol 11141-17-6. Azadirachtin. 95507-03-2. Azadirachtin B 68049-83-2. Azafenidin ...http://cischem.com/classify/cas_number_a.asp?data_part1=cas
Application # 2005/0002865. Diagnostic/therapeutic agents - Patents.com
... azacosterol, azacyclonol, azaftozine, azaguanidine, azaloxan, azamethonium bromide, azamulin, azanator, azanidazole, azaperone ...http://www.patents.com/us-20050002865.html
Torcetrapib - Wikipedia
On December 2, 2006 Pfizer cut off torcetrapibs phase III trial because of "an imbalance of mortality and cardiovascular events" associated with its use. This was a sudden and unexpected event and as late as November 30, 2006 Jeff Kindler, Pfizers chief executive, was quoted, "This will be one of the most important compounds of our generation." In the terminated trial, a 60% increase in deaths was observed among patients taking torcetrapib and atorvastatin versus taking atorvastatin alone. Pfizer recommended that all patients stop taking the drug immediately. Six studies were terminated early. One of the completed studies found it raised systolic blood pressure and concluded "Torcetrapib showed no clinical benefit in this or other studies, and will not be developed further." The drug cost $800m+ to bring into Phase III development. ...https://en.wikipedia.org/wiki/Torcetrapib
Atorvastatin - Wikipedia
Interactions with clofibrate, fenofibrate, gemfibrozil, which are fibrates used in accessory therapy in many forms of hypercholesterolemia, usually in combination with statins, increase the risk of myopathy and rhabdomyolysis. Co-administration of atorvastatin with one of CYP3A4 inhibitors such as itraconazole, telithromycin, and voriconazole, may increase serum concentrations of atorvastatin, which may lead to adverse reactions. This is less likely to happen with other CYP3A4 inhibitors such as diltiazem, erythromycin, fluconazole, ketoconazole, clarithromycin, cyclosporine, protease inhibitors, or verapamil, and only rarely with other CYP3A4 inhibitors, such as amiodarone and aprepitant. Often, bosentan, fosphenytoin, and phenytoin, which are CYP3A4 inducers, can decrease the plasma concentrations of atorvastatin. Only rarely, though, barbiturates, carbamazepine, efavirenz, nevirapine, oxcarbazepine, rifampin, and rifamycin, which are also CYP3A4 inducers, can ...https://en.wikipedia.org/wiki/Atorvastatin
Cholesterol | CTD
Azacosterol dicholesteroyl diselenide DT01 compound EpiCeram ergosta-. 6,9,22-. triene-. 3,5,8-. triol ...http://ctd.mdibl.org/detail.go?type=chem&acc=D002784
MICRO-RNAS OF THE MIR-15 FAMILY MODULATE CARDIOMYOCYTE SURVIVAL AND CARDIAC REPAIR - Patent application
0090] Non-limiting examples of miscellaneous antihyperlipoproteinemics include acifran, azacosterol, benfluorex, β- ...http://www.patentsencyclopedia.com/app/20140051745
Azacosterol. Thorium Oxide. Etomidate. Alvimopan. ©2016 DrugLead US FDA&EMEA. ...http://www.druglead.com/cds/thiopental-sodium.html
Hitchhiker's Guide to the Galaxy on Statin
In 2016 the United States Preventive Services Task Force recommended statins for those who have at least one risk factor for coronary heart disease, are between 40 and 75 years old, and have at least a 10% 10-year risk of heart disease. The risk factors for coronary heart disease included abnormal lipid levels in the blood, diabetes mellitus, high blood pressure, and smoking. The risk of heart disease is estimated using the ACC/AHA Pooled Cohort equation. They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5-10% or greater. Most evidence suggests that statins are effective in preventing heart disease in those with high cholesterol, but no history of heart disease. A 2013 Cochrane review found a decrease in risk of death and other poor outcomes without any evidence of harm. For every 138 people treated for 5 years one fewer dies and for every 49 treated one fewer has an episode ...http://hitchhikersgui.de/Statin
Azacosterol. Drotaverine. Lazurite. Methyl Ethyl Ketone. Turanose. DMMP. Azintamide. Probenecid. Sulfurous Acid. Rhodopsin. ...http://www.druglead.com/cds/propipocaine.html
CAS # 320-67-2, 5-Azacytidine, 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one
8-tetrahydro-1-naphthalenecarboxamide 3-Azacarbazole 2-Azacarbazole Azaconazole Azacosterol Azacosterol hydrochloride 1-Aza-2- ...https://www.chemblink.com/products/320-67-2.htm
After over two years of testing and lobbying by AMT, Glybera was approved in Europe in 2012. However, after spending millions of euros on Glyberas approval, AMT went bankrupt and its assets were acquired by uniQure N.V.. Alipogene tiparvovec was expected to cost around $1.6 million per treatment in 2012-revised to $1 million in 2015-making it the most expensive medicine in the world at the time. However, replacement therapy, a similar treatment, can cost over $300,000 per year, for life. In 2015, uniQure dropped its plans for approval in the US and exclusively licensed rights to sell the drug in Europe to Chiesi Farmaceutici for €31 million. As of 2016, only one person had received the drug outside of a clinical trial. In April 2017, Chiesi quit selling Glybera and uniQure announced that it would not pursue the renewal of the marketing authorization in Europe when it was scheduled to expire that October, due to lack of demand. Afterwards, the three remaining ...https://readtiger.com/wkp/en/Alipogene_tiparvovec
Azacosterol. Santonica. Flopropione. Trichloroethylene. Resazurin. Chamomile. 4,4-Methylenebis[2-chloroaniline]. ©2016 ...http://www.druglead.com/cds/Hemicelluloses.html
98977-34-5 | N-Boc-3-carboethoxy-4-piperidone | Chiralblock
Chiralblock CB13539 CAS No.98977-34-5.N-Boc-3-carboethoxy-4-piperidone;N-Boc-3-carboethoxy-4-piperidone,MFCD01862189.http://www.chiralblock.com/product/CB13539.html
Azacosterol. Corytuberine. Thiodiglycolic Acid. Metformin. Quinacrine. ©2016 DrugLead US FDA&EMEA. ...http://www.druglead.com/cds/trapidil.html
Chemical Summary for Azacosterol
3 beta, 17 beta)-17[[3-Dimethylamino)propyl]methylamino]androst-5-en-3-ol, Dihydrochloride; 02026 (CA DPR Chem Code Text ); 098101 [US EPA PC Code, Text ]; 1249-84-9 (CAS number); 1249849; 1249849 (CAS number without hyphens); 20,25-Diazacholesterol dihydrochloride; 2026 (CA DPR Chem Code) ); 98101 [US EPA PC Code, Numeric ]; Androst-5-en-3-ol, 17-((3-(dimethylamino)propyl)methyl)amino)-, dihydrochloride, (3.beta.,17.beta.)-; Azacosterol; Azacosterol hydrochloride; Azocosterol HCl; ...http://docs.pesticideinfo.org/Summary_Chemical.jsp?Rec_Id=PRI1354
Azacosterol. Viscose. Cuprous Sulfide. Neuraminic Acid. Ellmans Reagent. Sulfabromomethazine. Polychlorinated Biphenyls. ...http://www.druglead.com/cds/aluminum-borate.html
Azacosterol. Achillea. Slendid®. Bezafibrate. Silicon. ©2016 DrugLead US FDA&EMEA. ...http://www.druglead.com/cds/paclitaxel.html